Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Quarterly results

Trius Therapeutics Inc (TSRX) Create: Alert

All | News | Filings
Date FiledTypeDescription
02/14/2014 SC 13G/A KPCB PANDEMIC & BIO DEFENSE FUND LLC reports a 0% stake in Trius Therapeutics, Inc.
09/13/2013 SC 13D/A CUBIST PHARMACEUTICALS INC has filed a Schedule 13D for Trius Therapeutics Inc
09/11/2013 SC 14D9/A Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
09/11/2013 8-K Quarterly results
09/11/2013 SC TO-T/A Form SC TO-T - Tender offer statement by Third Party [amend]
09/11/2013 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
09/05/2013 SC TO-T/A Form SC TO-T - Tender offer statement by Third Party [amend]
09/03/2013 SC TO-T/A Form SC TO-T - Tender offer statement by Third Party [amend]
08/29/2013 SC TO-T/A Form SC TO-T - Tender offer statement by Third Party [amend]
08/26/2013 SC 13D/A Form SC 13D - General statement of acquisition of beneficial ownership [amend]
08/14/2013 SC TO-T/A Form SC TO-T - Tender offer statement by Third Party [amend]
08/13/2013 SC 14D9 Form SC 14D9 - Solicitation, recommendation statements
08/13/2013 SC TO-T Form SC TO-T - Tender offer statement by Third Party
08/09/2013 SC 13D Trius Therapeutics Inc reports a 27.5% stake in TRIUS THERAPEUTICS, INC.
08/07/2013 10-Q Quarterly Report for the period ended June 30, 2013
08/06/2013 8-K Quarterly results
Docs: "TRIUS THERAPEUTICS REPORTS SECOND QUARTER 2013 FINANCIAL RESULTS"
08/02/2013 SC TO-C Form SC TO-C - Written communication relating to an issuer or third party
08/01/2013 SC TO-C Form SC TO-C - Written communication relating to an issuer or third party
08/01/2013 SC TO-C Form SC TO-C - Written communication relating to an issuer or third party
07/30/2013 SC TO-C Form SC TO-C - Written communication relating to an issuer or third party
07/25/2013 8-K Entry into a Material Definitive Agreement
05/08/2013 10-Q Quarterly Report for the period ended March 31, 2013
05/07/2013 8-K Quarterly results
Docs: "TRIUS THERAPEUTICS REPORTS FIRST QUARTER 2013 FINANCIAL RESULTS"
04/15/2013 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/25/2013 8-K Other Events, Financial Statements and Exhibits
Docs: "TRIUS ANNOUNCES POSITIVE RESULTS FROM ESTABLISH 2 STUDY OF TEDIZOLID IN SEVERE SKIN INFECTIONS",
"Trius Therapeutics, Inc. Presentation"
03/13/2013 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/13/2013 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans
03/13/2013 10-K Annual Report for the period ended December 31, 2012
03/12/2013 8-K Quarterly results
Docs: "TRIUS THERAPEUTICS REPORTS 2012 FOURTH QUARTER AND FULL YEAR 2012 FINANCIAL RESULTS"
02/11/2013 SC 13G/A Versant Side Fund III, L.P. reports a 8.3% stake in Trius Therapeutics, Inc.
01/18/2013 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Underwriting Agreement",
"Opinion of Cooley LLP",
"TRIUS THERAPEUTICS, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK",
"TRIUS THERAPEUTICS, INC. PRICES PUBLIC OFFERING OF COMMON STOCK"
01/18/2013 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]
01/18/2013 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]
01/07/2013 8-K Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
Docs: "TEDIZOLID RECEIVES QUALIFIED INFECTIOUS DISEASE PRODUCT DESIGNATION FROM FDA"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy